Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study
Abstract
Aim: To evaluate the efficacy of immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) as second-line treatment in patients with metastatic renal cell carcinoma (mRCC). Patients & methods: Baseline and follow-up data from patients with mRCC treated with second-line ICIs plus TKIs or TKIs alone from a single institution were retrospectively gathered. Results: A total of 110 patients were included. The objective response rate was higher among patients treated with ICIs plus TKIs than those treated with TKIs alone (36.5 vs 12.1%; p = 0.002). Treatment with ICIs plus TKIs was associated with longer progression-free survival (15.0 vs 9.0 months; p = 0.009) and overall survival (not reached vs 16.0 months; p = 0.018) than TKI monotherapy. The survival rates at 2 (83.0 vs 74.4%; p = 0.426) and 3 years (58.1 vs 47.5%; p = 0.214) between the two groups were not statistically different. Notably, patients with certain clinicopathological features tended to gain more survival benefits with combined therapy. Conclusion: ICIs plus TKIs showed superior progression-free survival time and tumor response rate over TKIs alone as second-line treatment in patients with mRCC. Future randomized prospective trials are necessary to validate these preliminary findings.
Plain language summary
Aim: To evaluate the efficacy of immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs) in patients with previously treated metastatic renal cell carcinoma (mRCC). Patients & methods: Data at initial treatment and follow-up of patients with mRCC with second-line ICIs plus TKIs or TKIs alone were documented. Results: A total of 110 patients were included. The tumor shrinkage rate was higher among patients treated with ICIs plus TKIs than those treated with TKIs alone. Patients receiving ICIs plus TKIs had delayed disease progression and longer survival time compared with patients treated with TKI monotherapy. However, patients had a similar probability of survival after 2 and 3 years of treatment. Notably, patients with certain clinicopathological characteristics gained more survival benefits from ICIs plus TKIs. Conclusion: ICIs plus TKIs showed superior efficacy over TKIs alone in previously treated patients with mRCC. Future randomized prospective trials are necessary to validate these preliminary findings.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
- 2. . ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(5), 706–720 (2020).
- 3. . International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67(3), 519–530 (2015).
- 4. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125–134 (2007).
- 5. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449–456 (2008).
- 6. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115–124 (2007).
- 7. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
- 8. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1103–1115 (2019).
- 9. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378(14), 1277–1290 (2018).
- 10. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1116–1127 (2019).
- 11. EAU guidelines on renal cell carcinoma: 2020. EAU Guidelines on Renal Cell Carcinoma: 2020. 67, 913–924 (2020).
- 12. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1814–1823 (2015).
- 13. Phase IB/II Trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 31(11), 1154–1163 (2015). • Reporting the superior efficacy of lenvatinib plus pembrolizumab in metastatic renal cell carcinoma patients with previous systematic treatment failure.
- 14. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931–1939 (2011).
- 15. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, Phase 2, open-label, multicentre trial. Lancet Oncol. 16(15), 1473–1482 (2015).
- 16. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol. Res. 3(9), 1017–1029 (2015).
- 17. A Phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy. J. Clin. Oncol. 38(Suppl. 6), 612 (2020). • Reporting the efficacy of novel receptor tyrosine kinase inhibitor sitravatinib in combination with nivolumab for metastatic renal cell carcinoma patients with tyrosine kinase inhibitor treatment failure.
- 18. . TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 32(1), 97–102 (2021). • A phase Ib trial reporting the efficacy and safety of tivozanib-nivolumab combination therapy in metastatic renal cell carcinoma patients with previous treatment failure.
- 19. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).
- 20. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 16(3), 293–300 (2015).
- 21. Improving IMDC prognostic prediction through evaluation of initial site of metastasis in patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 18(2), e83–e90 (2020).
- 22. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis? Clin. Genitourin. Cancer 16(5), 355–359.e1 (2018).
- 23. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14(2), 141–148 (2013).
- 24. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist 25(3), e484–e491 (2019).
- 25. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).
- 26. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
- 27. Biomarker analyses from the Phase III CheckMate 214 trial of nivolumab plus ipilimumab (N + I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 38(Suppl. 15), 5009 (2020).
- 28. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the Phase 3 JAVELIN Renal 101 trial. Nat. Med. 26(11), 1733–1741 (2020).
- 29. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018). •• Showing the association between genomic alternations and response to immune checkpoint therapies of clear cell renal cell carcinoma.
- 30. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol. 5, 1631–1633 (2019).
- 31. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24(6), 749–757 (2018).